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Aim. To identify novel FGFR1 inhibitors using virtual screening approach. Methods. We used 
methods of organic synthesis, molecular docking via the Autodock 4.2.6 program package and 
in vitro biochemical tests with γ-32P. Results. In vitro experiments showed that 9 of 23 tested 
compounds possess inhibitory activity against FGFR1 with IC50 values in the range from 0.9 
to 5.6 μM. Conclusions. Nine FGFR1 inhibitors were developed. The mode of compounds 
binding with the ATP-acceptor site was determined using molecular docking methods and the 
dependence of the compounds’ activity on the substituents R1, R4 and R5 was evaluated. 
K e y w o r d s: Fibroblast growth factor receptor 1, molecular docking, organic synthesis, 
in vitro testing, 4-methoxythieno[2,3-d]pyrimidin.
Introduction
Fibroblast growth factor receptor 1 (FGFR1) 
is a receptor tyrosine kinase. Normally this 
enzyme is involved in tissue repair, hemato-
poiesis, angiogenesis and embryonic develop-
ment. However, due to the FGFR role in regu-
lating cell growth and survival, amplification 
and/or mutation of this protein kinase drives a 
number of cancer types, including gastric can-
cer, multiple myeloma, breast cancer and non-
small cell lung cancer (NSCLC). Such inhibi-
tors of FGFR1 as AZD4547, E3810, G141 and 
E7090 showed anticancer potential and now 
are in clinical trials. This means that FGFR1 
is an appealing target for the drug development 
[1-4].
The main aim of this work was the search 
for new FGFR1 inhibitors among 4-metho xy-
thieno[2,3-d]pyrimidine derivatives. Earlier 
using molecular docking of the collection of 
the Department of medicinal chemistry 
(Institute of molecular biology and genetics, 
NAS of Ukraine) we identified several classes 
of FGFR1 inhibitors, such as N-phenylnaph-
thostyril-1-sulfonamides [5], N-phenyl thie-
no[2,3-d]py rimidin-4-amines [6], quinazolines 
[7], oxindoles [8], (1H-benzoimidazol-2-yl)-
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phenyl-1,2-dihydro-pyrrol-3-ones [9] and fla-
vones [10].
Materials and methods
Molecular docking
Preparation of ligands and receptor molecules. 
Autodock 4.2.6 programs package was used 
for the receptor-based flexible docking [11]. 
Ligands were prepared by Vega ZZ (command 
line) [12] and MGL Tools 1.5.6 [11]. The in-
coming formats of receptor and ligands data 
were converted into PDBQT-format with Vega 
ZZ using AUTODOCK force field. This format 
contains the coordinates of the atoms and par-
tial charges. Hydrogen atoms were removed 
from nonpolar atoms. The receptor was pre-
pared using MGL Tools and AutoGrid [11].
We have used docking parameters reported 
earlier [13].
Flexible docking. The catalytic subunit of 
protein kinase FGFR1 complex with inhibitor 
(PDB code 3GQI) was used for molecular 
docking via Autodock [14]. Water molecules, 
ions, and ligands were removed from the PDB 
file.
Visual analysis
A visual analysis of the results of molecular 
docking (interaction of compounds with the 
amino acid residues of FGFR1 ATP-binding 
site) was carried out in the Discovery Studio 
Visualizer 4.0 (http://accelrys.com/).
In vitro testing
The FGFR1 kinase assays with recombinant 
cytoplasmic domain of the FGFR1 tyrosine ki-
nase (Millipore, Cat. N. 14-582) were performed 
in a total volume of 30 μl containing 10 mM 
MOPS (рН 7.2), 0.1 mM sodium orthovanadate, 
0.2 mM EDTA, 0.002 % Brij 35, 0.2 mg/ml 
BSA, 0.02 % β-mercaptoethanol, 250 μM of 
peptide substrate (KKKSPGEYVNIEFG, 
GenScript), various concentrations of inhibitor 
dissolved in DMSO (final DMSO concentration 
in probe less than 1 %) and 10 mU of enzyme. 
The reaction was initiated by the addition of ATP 
(50 μM ATP, 25 mM MgAc containing 0.1 μCi 
of [γ-32P] ATP per probe) and samples incu-
bated at 30°C for 25 min. The reaction was 
terminated by the addition of 5 % phosphoric 
acid and the precipitation of material onto phos-
phocellulose filters “Whatman P81”. Filters were 
washed three times with 0.75 % phosphoric acid 
and the incorporation of [32P] into the peptide 
substrate was determined by counting the radio-
activity retained on the filters in a PerkinElmer 
scintillation counter. As negative control an 
equal volume of dimethyl sulfoxide (DMSO) 
was added to the reaction mixture. Inhibition 
percentage was calculated as a ratio of the sub-
strate-incorporated radioactivity in the presence 
of inhibitor to the radioactivity incorporated in 
control reactions, i.e. in the absence of inhibitor. 
The concentration of compound that inhibited 
enzymatic activity by 50 % (IC50) was deter-
mined graphically.
Chemistry
The thieno[2,3-d]pyrimidine derivatives were 
synthesized from corresponding carbonyl com-
pounds according to Scheme 1. Initially sub-
stituted 2-amino-3-carbethoxythiofenes (2) 
were obtained by Gewald reaction (in case of 
acetophenone [the] synthesis was carried out 
in two stages: firstly ethyl cyanoacetate was 
condensed with the corresponding acetophe-
none and then the product was cyclized with 
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sulfur) (method 1). Then thienopyrimidinones 
(3) were obtained by condensation of 2-amino-
3-carbethoxythiofenes with formamide (meth-
od 2). The various 4-chloro-thieno[2,3-d]py-
rimidines (4) were synthesized after interaction 
of thienopyrimidinones with PCl5 (method 3) 
and used as a building block for further forma-
tion of combinatorial rows. The final com-
pounds were obtained by chlorine substitution 
in previous molecules with corresponding phe-
nols (method 4a) or protected aminophenols 
(method 4b).
Experimental section
Starting materials and solvents were purchased 
from commercial suppliers and were used 
without further purification. The progress of 
the reaction and purity of obtained compounds 
were controlled by TLC on “Kieselgel 60 F254” 
plates (Merck). The structures of synthesized 
compounds were confirmed by 1H NMR spec-
trometry and liquid chromatography-mass 
spectra (LC-MS) analysis. Nuclear magnetic 
resonance spectra were recorded on a Varian 
Mercury VRX-400 spectrometer using 
DMSO-d6 as solvent and tetramethylsilane as 
internal standard. Chemical shift values (δ) are 
quoted in ppm and coupling constants (J) 
in Hz. Liquid chromatography-mass spectra 
(LC-MS) analyses were performed using the 
Agilent 1100 LC/MSD SL (Agilent Technolo-
gies) separations module and Mass Quad 
G1956B mass detector with electrospray ion-
ization (Agilent Technologies). HPLC is per-
formed using Zorbax SB-C18 (Agilent 
Technologies), Rapid Resolution HT Cartridge 
4.6x30 mm 1.8-µ (Agilent Technologies 
P/N:823975-902) i.d. column, at a temperature 
of 40 oC with gradient elution of 0–100 % 
CH3CN (with 1 mL/L HCOOH): H2O (with 
1 mL/L HCOOH) at a flow rate of 3 mL/min 
and a run time of 2.8 min. Compounds were 
detected at 215 nm using a Diode Array 
G1315B detector. All tested compounds had 
≥ 90 % purity as determined by this method. 
All purified synthetic intermediates had ≥ 95 % 
purity as determined by this method.
Method 1. A mixture of 107 mL (1 mol) of 
ethyl cyanoacetate, 32 g (1 mol) of elemental 
sulfur and 1 mol of the corresponding ketone 
C2H5OH
HCONH2(C2H5)2NHS,
PCl5, POCl3
2 3
4  5 - 27
A: DMF/NaH
B: neat (no solvent)
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Scheme 1. General synthesis of compounds 5-27.
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in 200 ml of ethanol was stirred at room tem-
perature. 80 ml of diethylamine were added to 
this mixture for 12 h. The reaction mixture was 
left overnight; the precipitate was filtered, 
washed by aqueous alcohol (1:1) and dried in 
air [15]. Yield was 50-88 %.
Method 2. 2 mol of formamide were added 
to 1 mol 2-aminothiophene and the mixture 
was heated to 160-170oC for 24 h. The hot 
mixture was diluted with isopropyl alcohol and 
cooled. The solid product was collected by 
filtration, washed with isopropyl alcohol and 
water and dried at 60oC [16]. Yield was 85-
90 %.
Method 3. A mixture of 0.01 mol of thieno-
pyrimidinone, 11 ml of POCl3 and 1.5 g PCl5 
was refluxed for 5-6 hours. The solvent was 
carefully evaporated to dryness. The dry prod-
uct was dissolved in methylene chloride and 
poured to a cold 0.5 N NaOH solution. The 
organic phase was separated and dried with 
anhydrous Na2SO4, then solvent was evapo-
rated in vacuum. The residue was recrystal-
lized from isopropanol [17]. Yield was 70-
80 %.
Method 4A. NaH (60 % dispersion in min-
eral oil) (0.5g, 0.012 mol) was added to solu-
tion of 0.011 mol of corresponding phenol in 
10 ml of dimethylformamide at 0oC, after 30 
minutes at ambient temperature 0.01 mol of 
substituted 4-chloro-thieno[2,3-d]pyrimidine 
was added and the mixture was stirred at 80oC 
for 8 hours. The content of the flask was di-
luted with water. Precipitate was filtered off 
and dried at room temperature. The resulting 
solid was recrystallized from ethanol. Yield 
was 60-80 %.
Method 4B. A mixture of 0.01 mol N-(4-
hydroxy-phenyl)-acetamide (or N-(3-hydroxy-
phenyl)-acetamide) and 0.01 mol of substi-
tuted 4-chloro-thieno[2,3-d]pyrimidine was 
melted at 180°C for 30 min. Saturated sodium 
carbonate solution was added and the precipi-
tate was filtered, washed with water and dried. 
The residue was recrystallized from mixture 
of N,N-dimethylformamide and ethanol (for 
compounds 6,10,12,23,24). Yield 50-60 %.
4-(4-methylphenoxy)-5,6,7,8-tetrahydro[1]
benzothieno[2,3-d]pyrimidine (5). Yellow 
solid, m.p. 102-104°С; 1H NMR (DMSO-d6) 
δ: 1.90 (s, 4H, CH2), 2.35 (s, 3H, CH3), 2.75 
(s, 2H, CH2), 3.05 (s, 2H, CH2), 7.08 (d, J = 
8.3 Hz, 2H, C6H4), 7.22 (d, J = 8.3 Hz, 2H, 
C6H4), 8.37 (s, 1H, pyrimidine). LC-MS: m/z 
297.0 [M+H]+. Yield 65 %.
N-{3-[(5-phenylthieno[2,3-d]pyrimidin-
4-yl)oxy]phenyl}acetamide (6).  Brown solid, 
m.p. 190-191°С; 1H NMR (DMSO-d6) δ: 2.03 
(s, 3H, CH3), 6.82 (s, 1H, pyrimidine), 7.28-7.5 
(m, 5H, C6H5), 7.62 (m, 3H, Ar), 7.8 (s, 1H, 
Ar), 8.6 (s, 1H, pyrimidine), 9.92 (s, 1H, NH). 
LC-MS: m/z 362.0 [M+H]+. Yield 50 %.
7-{[5-(4-bromophenyl)thieno[2,3-d]pyrim-
idin-4-yl]oxy}-2H-chromen-2-one (7).  White 
solid, m.p. 216-217°С; 1H NMR (DMSO-d6) 
δ: 6.43 (m, 1H, CH), 7.18 (m, 1H, CH), 7.36 
(s, 1H, pyrimidine), 7.58 (m, J = 7.6 Hz, 2H, 
C6H4), 7.63 (d, J = 7.6 Hz, 2H, C6H4), 7.75-
8.08 (m, 3H), 8.63 (s, 1H, pyrimidine), LC-
MS: m/z 450.9 [M+H]+. Yield 65 %.
4-(1,3-benzodioxol-5-yloxy)-5-(4-chloro-
phenyl)thieno[2,3-d]pyrimidine (8). Yellow 
solid, m.p. 156-158°С. 1H NMR (DMSO-d6) 
δ: 6.08 (s, 2H, CH2), 6.7 (m, 1H, Ar), 6.92-7.06 
(m, 2H, Ar), 7.52 (d, J = 7.6 Hz, 2H, C6H4), 
7.72 (d, J = 7.6 Hz, 2H, C6H4), 7.94 (s, 1H, 
pyrimidine), 8.67 (s, 1H, pyrimidine). LC-MS: 
m/z 383.0 [M+H]+. Yield 80 %.
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1-(4-{[5-(4-methylphenyl)thieno[2,3-d]
pyrimidin-4-yl]oxy}phenyl)ethanone (9). 
White solid, m.p. 134-135°С; 1H NMR 
(DMSO-d6) δ: 2.35 (s, 3H, CH3), 2.58 (s, 3H, 
CH3), 7.2 (d, J = 7.8 Hz, 2H, C6H4), 7.29 (d, 
J = 7.8 Hz, 2H, C6H4), 7.53 (d, J = 7.6 Hz, 2H, 
C6H4), 7.74 (s, 1H, pyrimidine), 8.02 (d, J = 
7.6 Hz, 2H, C6H4), 8.57 (s, 1H, pyrimidine). 
LC-MS: m/z 361.0 [M+H]+. Yield 72 %.
N-(4-{[5-(4-methylphenyl)thieno[2,3-d]
pyrimidin-4-yl]oxy}phenyl)acetamide (10). 
White solid, m.p. 204-205°С; 1H NMR 
(DMSO-d6) δ: 2.03 (s, 3H, CH3), 2.33 (s, 3H, 
CH3), 7.04 (d, J = 7.6 Hz, 2H, C6H4), 7.21 (d, 
J = 6.3 Hz, 2H, C6H4), 7.52 (d, J = 6.3 Hz, 2H, 
C6H4), 7.58 (d, J = 7.6 Hz, 2H, C6H4),7.69 (s, 
1H, pyrimidine), 8.53 (s, 1H, pyrimidine), 9.91 
(s, 1H, NH). LC-MS: m/z 376.0 [M+H]+. Yield 
58 %.
4 - ( 3 - c h l o r o - 4 - f l u o r o p h e n o x y ) -
5-phenylthieno[2,3-d]pyrimidine (11). Blue 
solid, m.p. 143-145°С; 1H NMR (DMSO-d6) 
δ: 7.16-7.2 (m, 1H, Ar), 7.33-7.49 (m, 5H, Ar), 
7.65 (d, 2H, Ar), 7.78 (s, 1H, pyrimidine), 8.57 
(s, 1H, pyrimidine). LC-MS: m/z 357.0 
[M+H]+. Yield 76 %.
N-(3-{[5-(4-methoxyphenyl)thieno[2,3-d]
pyrimidin-4-yl]oxy}phenyl)acetamide (12). 
Cream solid, m.p. 160-161°С; 1H NMR 
(DMSO-d6) δ: 2.03 (s, 3H, CH3), 3.77 (s, 3H, 
CH3), 6.96 (d, J = 8.1 Hz, 2H, C6H4), 7.28-7.37 
(m, 3H, Ar), 7.5 (s, 1H, Ar), 7.58 (d, J = 8.1 Hz, 
2H, C6H4), 7.78 (s, 1H, pyrimidine), 8.62 (s, 
1H, pyrimidine), 10.06 (s, 1H, NH). LC-MS: 
m/z 392.0 [M+H]+. Yield 58 %.
4-(1,3-benzodioxol-5-yloxy)-5-(4-methyl-
phenyl)thieno[2,3-d]pyrimidine (13). White 
solid, m.p. 145-147°С; 1H NMR (DMSO-d6) 
δ: 2.31 (s, 3H, CH3), 2.49 (s, 2H, CH2), 6.05 
(s, 1H, Ar), 6.89-6.94 (m, 2H, Ar), 7.21 (d, J = 
7.8 Hz, 2H, C6H4), 7.56 (d, J = 7.8 Hz, 2H, 
C6H4), 7.79 (s, 1H, pyrimidine), 8.62 (s, 1H, 
pyrimidine). LC-MS: m/z 363.0 [M+H]+. Yield 
73 %.
4-(quinolin-8-yloxy)-5,6,7,8-tetrahydro[1]
benzothieno[2,3-d]pyrimidine (14). Yellow 
solid, m.p. 193-194°С; 1H NMR (DMSO-d6) 
δ: 1.93 (s, 4H, CH2), 2.91 (s, 4H, CH2),7.48-
7.72 (m, 3H, Ar), 7.92 (d, J= 8.1 Hz, 1 H, Ar, 
quinoline), 8.18(s, 1H, Ar, quinoline), 8.39 (d, 
J = 8.1 Hz, 1H, Ar, quinoline), 8.68 (s, 1H, 
pyrimidine). LC-MS: m/z 334.0 [M+H]+. Yield 
60 %.
4-(4-bromophenoxy)-5,6,7,8-tetrahydro[1]
benzothieno[2,3-d]pyrimidine (15). Cream 
solid, m.p. 90-91°С; 1H NMR (DMSO-d6) δ: 
1.86 (s, 4H, CH2), 2.87 (s, 2H, CH2), 3.00 (s, 
2H, CH2), 7.27 (d, J = 7.6 Hz, 2H, C6H4), 7.65 
(d, J = 7.6 Hz, 2H, C6H4), 8.47 (s, 1H, py-
rimidine). LC-MS: m/z 360.9 [M+H]+. Yield 
72 %.
4-(4-fluorophenoxy)-5,6,7,8-tetrahydro[1]
benzothieno[2,3-d]pyrimidine (16). Cream 
solid, m.p. 89-91°С; 1H NMR (DMSO-d6) δ: 
1.78 (m, 4H, CH2), 2.75 (s, 2H, CH2), 3.08 (s, 
2H, CH2), 7.43 (m, 4H, C6H4), 8.38 (s, 1H, 
pyrimidine). LC-MS: m/z 301.0 [M+H]+. Yield 
75 %.
4-(3-methylphenoxy)-5,6,7,8-tetrahydro[1]
benzothieno[2,3-d]pyrimidine (17). Brown 
solid, m.p. 95-96°С; 1H NMR (DMSO-d6) δ: 
1.87-1.96 (m, 4H, CH2), 2.33 (s, 3H, CH3), 2.75 
(s, 2H, CH2), 3.00 (s, 2H, CH2), 7.03-7.11 (m, 
3H, Ar), 7.26 (m, 1H, Ar), 8.23 (s, 1H, pyrimi-
dine). LC-MS: m/z 297.0 [M+H]+. Yield 65 %.
4 - ( 2 , 4 - d i c h l o r o p h e n o x y ) - 5 , 6 -
dimethylthieno[2,3-d]pyrimidine (18). White 
solid, m.p. 125°С; 1H NMR (DMSO-d6) δ: 
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2.53 (s, 6H, CH3), 7.57 (d, 2H, Ar), 7.84 (s, 
1H, Ar), 8.50 (s, 1H, pyrimidine). LC-MS: m/z 
324.9 [M+H]+. Yield 62 %.
4-[3-(trifluoromethyl)phenoxy]-6,7,8,9-
tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]
pyrimidine (19). White solid, m.p. 83-84°С; 
1H NMR (DMSO-d6) δ: 1.72 (m, 4H, CH2), 
1.89 (m, 2H, CH2), 2.96 (m, 2H, CH2), 3.25 
(m, 2H, CH2), 7.59-7.78 (m, 4H, Ar), 8.48 (s, 
1H, pyrimidine). LC-MS: m/z 365.0 [M+H]+. 
Yield 71 %.
dimethyl 5-{[5-(4-methylphenyl)thieno[2,3-
d]pyrimidin-4-yl]oxy}isophthalate (20). Light 
brown solid, m.p. 103-105°С; 1H NMR 
(DMSO-d6) δ: 2.33 (s, 3H, CH3), 3.12 (s, 3H, 
CH3), 3.89 (s, 3H, CH3), 7.32 (d, J = 7.8 Hz, 
2H, C6H4), 7.58 (d, J = 7.8 Hz, 2H, C6H4), 7.76 
(s, 1H, Ar), 7.98 (s, 2H, Ar), 8.39 (s, 1H, py-
rimidine), 8.60 (s, 1H, pyrimidine). LC-MS: 
m/z 435.0 [M+H]+. Yield 61 %.
7-[(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)
oxy]-4-methyl-2H-chromen-2-one (21). White 
solid, m.p. 275-276°С; 1H NMR (DMSO-d6) δ: 
2.58 (s, 6H, CH3), 3.05 (s, 3H, CH3), 6.28 (s, 
1H, CH), 7.28 (m, 1H, Ar), 7.32 (m, 1H, Ar), 
7.80 (m, 1H, Ar) 8.45 (s, 1H, pyrimidine). LC-
MS: m/z 339.0 [M+H]+. Yield 72 %.
5-phenyl-4-[3-(trifluoromethyl)phenoxy]
thieno[2,3-d]pyrimidine (22). White solid, 
m.p. 124-126°С; 1H NMR (DMSO-d6) δ: 7.34-
7.50 (m, 3H, Ar), 7.60 (s, 1H, Ar), 7.63-7.70 
(m, 5H, C6H5), 7.83 (s, 1H, pyrimidine), 8.61 
(s, 1H, pyrimidine). LC-MS: m/z 373.0 
[M+H]+. Yield 75 %.
N-{4-[(5,6-dimethylthieno[2,3-d]pyrimidin-
4-yl)oxy]phenyl}acetamide (23). White solid, 
m.p. 202-203°С; 1H NMR (DMSO-d6) δ: 2.07 
(s, 3H, CH3), 2.57 (s, 3H, CH3), 3.11 (s, 3H, 
CH3), 7.08 (d, J = 7.6 Hz, 2H, C6H4), 7.62 (d, 
J = 7.6 Hz, 2H, C6H4), 8.37 (s, 1H, pyrimi-
dine), 9.87 (s, 1H, NH). LC-MS: m/z 314.0 
[M+H]+. Yield 56 %.
N-[3-(6,7-dihydro-5H-cyclopenta[4,5]
thieno[2,3-d]pyrimidin-4-yloxy)phenyl]acet-
amide (24). Grey solid, m.p. 197-198°С; 1H 
NMR (DMSO-d6) δ: 2.03 (s, 3H, CH3), 2.43-
2.58 (m, 2H, CH2), 3.03-3.18 (m, 4H, CH2), 
6.77 (d, 1H, Ar), 7.23 (m, 1H, Ar), 7.38 (d, 
1H, Ar), 7.56 (s, 1H, Ar), 8.33 (s, 1H, pyrimi-
dine), 9.78 (s, 1H, NH). LC-MS: m/z 326.0 
[M+H]+. Yield 53 %.
6-methyl-5-phenyl-4-[3-(trifluoromethyl)
phenoxy]thieno[2,3-d]pyrimidine (25). White 
solid, m.p. 161-163°С; 1H NMR (DMSO-d6) 
δ: 2.83 (s, 3H, CH3), 7.21-7.53 (m, 9H, Ar), 
8.43 (s, 1H, pyrimidine). LC-MS: m/z 387.0 
[M+H]+. Yield 78 %.
Methyl 4-[(6-methyl-5-phenylthieno[2,3-d]
pyrimidin-4-yl)oxy]benzoate (26). Grey solid, 
m.p. 147-148°С; 1H NMR (DMSO-d6) δ: 3.20 
(s, 3H, CH3), 3.87 (s, 3H, CH3), 7.17 (d, J = 
7.8 Hz, 2H, C6H4), 7.33-7.58 (m, 5H, C6H5) 7.96 
(d, J = 7.8 Hz, 2H, C6H4), 8.53 (s, 1H, pyrimi-
dine). LC-MS: m/z 377.0 [M+H]+. Yield 69 %.
7-methyl-4-[3-(trifluoromethyl)phenoxy]-
5,6,7,8-tetrahydro[1]benzothieno[2,3-d]py-
rimidine (27). Yellow solid, m.p. 95-96°С; 1H 
NMR (DMSO-d6) δ: 1.11 (d, 3H, CH3), 1.40-
1.58 (m, 1H, CH), 1.88-2.04 (m, 2H, CH2), 
2.88-3.02 (m, 2H, CH2), 3.15-3.23 (m, 2H, 
CH2), 7.62-7.78 (m, 4H, Ar), 8.51 (s, 1H, py-
rimidine). LC-MS: m/z 365.0 [M+H]+. Yield 
69 %.
Results and Discussion
Previously N-phenylthieno[2,3-d]pyrimidin-
4-amines were identified as FGFR1 inhibitors 
[6]. In this study 4-methoxythieno[2,3-d]py-
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Table 1. Structure, in vitro inhibitory activity toward FGFR1 and IC50 of studied compounds.
R1
R1
R3
R4
R5
R6
S
O
N
N
Com-
pound R
1 R2 R3 R4 R5 R6
Residual activity of 
FGFR1 at, % IC50, µM
33 µM 10 µM
5 -(CH2)4- H H Me H 33.8 41.7 4.47
6 phenyl H H H NAc H 24.5 N/A 2.3
7 4-bromophenyl H H
O O
O
O
O
O
N
O O
H 14.7 40.3 2.45
8 4-chlorophenyl H H
O O
O
O
O
O
N
O O
H 29.6 30.1 2.14
9 4-methylphenyl H H H Ac H 26.9 N/A 5
10 4-methylphenyl H H H NAc H 27.7 N/A 2.5
11 phenyl H H Cl F H 21.8 33,1 3.55
12 4-methoxyphenyl H H H NAc H 19.3 N/A 5.6
13 4-methylphenyl H H
O O
O
O
N
O O
H 15.1 17.4 0.9
14 -(CH2)4-
O O
O
O
O
O
N
O O
H H N/A 86,5 N/A
15 -(CH2)4- H H Br H 52 N/A N/A
16 -(CH2)4- H H F H 50.4 N/A N/A
17 -(CH2)4- H Me H H 65.3 N/A N/A
18 Me Me Cl H Cl H 88.2 N/A N/A
19 -(CH2)5- H CF3 H H 64.3 N/A N/A
20 4-methylphenyl H H COOMe H COOMe 53.2 83.7 N/A
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rimidines have been synthesized and tested 
toward FGFR1 kinases.
Twenty three 4-methoxythieno[2,3-d]py-
rimidines were evaluated for ability to inhibit 
the FGFR1 activity using 32P-ATP radiolabeled 
assay. This method provides direct measure-
ment of the enzyme activity. The results are 
summarized in Table 1. Nine compounds 
showed inhibitory activity with IC50 value 
from 0.9 to 5.6 µM.
To understand the activity of the compounds 
and make some conclusions about SAR we 
have performed molecular docking and ana-
lyzed the complexes of studied compounds 
with FGFR1 ATP-binding pocket to propose 
their binding mode. The complex of the most 
active found compound with the ATP-acceptor 
site of FGFR1 is shown in Fig. 1.
Proposed binding mode of the studied com-
pounds belongs to the type I protein kinases 
inhibitors. The thieno[2,3-d]pyrimidine core 
is located in adenine binding region and forms 
Ended Table 1
Com-
pound R
1 R2 R3 R4 R5 R6
Residual activity of 
FGFR1 at, % IC50, µM
33 µM 10 µM
21 Me Me H
O O
O
O
O
O
N
O O
H N/A N/A N/A
22 phenyl H H CF3 H H 70.4 N/A N/A
23 Me Me H H NAc H 65.8 N/A N/A
24 -(CH2)3- H NAc H H N/A N/A N/A
25 phenyl Me H CF3 H H 53.5 90.5 N/A
26 phenyl Me H H COOMe H 42.7 50 N/A
27
O O
O
O
O
O
N
O O
H CF3 H H 80 N/A N/A
Fig. 1. The complex of compound 13 with ATP-acceptor 
site of FGFR1 obtained with Autodock 4.2.6. H-bonds 
are shown by green dashed lines, hydrophobic interac-
tions – purple dashed lines.
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hydrogen bond with the amino acid residue 
Ala564 of the hinge region. Most R3-R6 sub-
stituents are extended towards hydrophobic 
region I and form hydrophobic interactions 
with Ala512 and Val561 and hydrogen bonds 
with Lys514 or Asp641. R1-R2 substituents are 
oriented to hydrophobic region II and form 
hydrophobic interactions with Val492 and/or 
Leu630 and/or Leu484. As exceptions were 
the compounds 14, 15, 16, 19 and 24 with 5- 
and 6-membered cycles at R1-R2. R1-R2 sub-
stituents of these compounds are oriented to 
the hydrophobic region I and R3-R6 substitu-
ents are oriented to the outer of binding site.
The Structure Activity Relationship (SAR) 
study showed that R1 of the most active com-
pounds is phenyl. Mostly it is a hydrophobic 
4-substituted phenyl. The compound 10 with 
4-methylphenyl (more hydrophobic) at R1 has 
two-fold higher activity than compound 12 
with 4-methoxyphenyl at R1. IC50 values were 
2.5 and 5.6 µM respectively. But the com-
pound 8 with 4-chlorophenyl (more hydropho-
bic) at R1 has lower activity than compound 
13 with 4-methylphenyl. IC50 values were 2.14 
and 0.9 µM, respectively. Therefore, the order 
of potency for the substituents at R1 could be 
proposed as following: 4-methylphenyl 
>4-chlorophenyl >4-methoxyphenyl.
SAR study of substituents at R3-R6 showed 
that the most active compounds have hydrogen 
bond acceptor at positions R4 and/or R5. 
Compounds 8 and 13 contain dioxymethan and 
have IC50 values of 2.14 and 0.9 µM, respec-
tively.
Conclusions
Nine new inhibitors of FGFR1 were discov-
ered among 23 4-methoxythieno[2,3-d]py-
rimidine derivatives. SAR study showed that 
the most profitable substituent at R1 is 4-meth-
ylphenyl and hydrogen bond acceptors at R4 
and/or R5 are important for revealing the in-
hibitory activity toward FGFR1. The most 
potent compound in this series showed the IC50 
value of 0.9 µM. The studied compounds are 
good candidates for the further development 
of effective FGFR1 inhibitors and potential 
anti-cancer drugs. 
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Ідентифікація інгібіторів FGFR1 серед 
4-метокситієно[2,3-d]піримідинів. 
І. М. Котей, М. В. Протопопов, С. А. Старосила, 
А. О. Баланда, Л. В. Плетньова, А. О. Приходько, 
В. Г. Бджола та С. М. Ярмолюк
Мета. Пошук нових інгібіторів протеїнкінази FGFR1. 
Методи. В роботі використовувались методи органіч-
ного синтезу, молекулярний докінг програмним пакетом 
Autodock 4.2.6 та біохімічне тестування in vitro із ви-
користанням γ-32P ATФ. Результати. Експерименти in 
vitro показали, що 9 з 23 сполук проявляють інгібуваль-
ну активність щодо FGFR1 зі значенням IC50 в межах 
від 0.9 до 5.6 µМ. Висновки. Було розроблено дев’ять 
інгібіторів FGFR1. За допомогою методів молекуляр-
ного моделювання було визначено спосіб зв’язування 
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із АТФ-акцепторним сайтом та вивченозалежність 
активності сполук від замісників R1, R4 та R5.
К л юч о в і  с л о в а. Протеїнкіназа FGFR1, молекуляр-
ний докінг, органічний синтез, in vitro тестування.
Идентификация ингибиторов FGFR1 среди 
4-метокситиено[2,3-d]пиримидинов
И. М. Котей, Н. В. Протопопов, С. А. Старосила, 
Л. В. Плетнёва, А. А. Приходько, А. А. Баланда, 
В. Г. Бджола и С. М. Ярмолюк
Цель. Поиск новых химических соединений со спо-
собностью ингибировать протеинкиназу FGFR1. 
Методы. В работе использовались методы органиче-
ского синтеза, молекулярного докинга программным 
пакетом Autodock 4.2.6 и биохимическое тестирование 
in vitro, используя γ-32P ATФ. Результаты. 
Биохимическое тестирование показало, что 9 из 23 
исследуемых соединений ингибируют протеинкиназу 
FGFR1 в диапазоне значений IC50 от 0.9 до 5.6 µМ. 
Выводы. Было разработано девять  ингибиторов 
FGFR1. С помощью молекулярного докинга было 
определено положение лигандов в АТФ-акцепторном 
сайте и изучено зависимость активности от структуры 
заместителей R1, R4 та R5.
К л юч е в ы е  с л ов а: Протеинкиназа FGFR1, моле-
кулярный докинг, органический синтез, in vitro тести-
рование, 4-метокситиено[2,3-d]пиримидин.
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